Medical News

RSS

Genentech updates on phase III study of Avastin plus chemo in first-line, advanced, non-squamous, non-small cell lung cancer

Genentech, Inc. has announced an update for the previously reported Roche-sponsored international Phase III clinical study (AVAiL) of Avastin (bevacizumab) in combination with gemcitabine and cisplatin chemotherapy, in patients with advanced, non-squamous, non-small cell lung cancer (NSCLC).

21 Apr 2008

Obesity, inactivity as common among cancer survivors as rest of Canadians

New research supported by the Canadian Cancer Society shows that many cancer survivors in Canada are overweight and inactive, which could put them at risk for health problems, including their cancer returning.

21 Apr 2008

US lags Europe in highly relevant nano risk research

A new analysis by the Project on Emerging Nanotechnologies (PEN) indicates that European nations are investing nearly twice as much as the U.S. in research primarily aimed at addressing the potential risks of nanotechnology.

21 Apr 2008

Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction?

In a definitive critical review, scientists at Children's Hospital & Research Center Oakland ask whether there is convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction.

21 Apr 2008

Physical activity and obesity in Canadian cancer survivors

A new study reveals that many cancer survivors are inactive and obese, which may negatively affect the control of their disease.

21 Apr 2008

The limits of observational data in determining outcomes from cancer therapy

Certain biases may exist in observational studies that compare outcomes of different cancer therapies, making the results questionable.

21 Apr 2008

New method for testing treatments for Chagas' disease

Chagas' disease is a tropical parasitic sickness that currently affects more than 16 million people, with a staggering 100 million at risk, largely in the tropical areas of South and Central America. And yet the main drug used to treat the disease is highly toxic and causes serious side effects.

20 Apr 2008

Chronic inflammation triggers cell fusions that could protect neurons

Chronic inflammation triggers bone marrow-derived blood cells to travel to the brain and fuse with a certain type of neuron up to 100 times more frequently than previously believed, according to a new study from the Stanford University School of Medicine.

20 Apr 2008

GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure

About 40 percent of African-Americans have a genetic variant that can protect them after heart failure and prolong their lives, according to research conducted at Washington University School of Medicine in St. Louis and collaborating institutions.

20 Apr 2008

Social networking, malaria and philanthropy partnership

Philanthropy just got easier and a lot more accessible to the public thanks to the social networking power of the Internet and a ground-breaking partnership between a young British entrepreneur, a global health think tank and an African medical research institute.

20 Apr 2008

A genetic variation mimics effect of heart failure medications - may explain why beta-blockers do not work for all patients

A genetic variation, found predominantly in African Americans, protects some people with heart failure, enabling them to live longer than expected. That's the conclusion of a research team led by investigators at the University of Maryland School of Medicine in Baltimore and the Washington University School of Medicine in St. Louis.

20 Apr 2008

Dental sealants still offer best protection against tooth decay says the BC Dental Association

Dental sealants remain one of the best methods for protection against tooth decay in children, says the BC Dental Association. The Association supports Health Canada's announcement that bisphenol-A (BPA) in dental resin materials poses no significant health threat.

20 Apr 2008